A Phase 3 interventional study of KK8398 in Achondroplasia, sponsored by Kyowa Kirin Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Kyowa Kirin Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Achondroplasia with a site in Japan — 1 open to participants now, 4 under way, 3 of them phase 3. Achondroplasia · Japan.
Among the 11 studies in Achondroplasia with a site in Japan, this one is the only one that started in 2024, is one of 3 in phase 3, and was the 10th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →1 of the 11 studies in Achondroplasia with a site in Japan is open now. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in Japan, United States, Australia and 6 more countries
Ages 2–17
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 4
First in 1997; this study’s year is marked. 1 started in 2024.
This study's enrollment of 13 is below the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 75 across the 7 interventional studies, 339 across the 4 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 4 most frequent:
Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.
Kyowa Kirin Co., Ltd. has 1 study filed under Achondroplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Achondroplasia with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: KK8398
KK8398 will be administered.
Change from baseline in annualized height velocity
Time frame: Pre-dose, Week 52
Height Z-score using growth tables in patients with achondroplasia and the change from baseline
Time frame: Pre-dose, Week 52
Plan to share: No — There is not a plan to make IPD available.
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for May 2029, 53 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.